Pay in 4 interest-free payments of $6.41 Learn more
Ships within 48 hours · Estimated delivery Aug 28 - Sep 2
Podcasts & Videos In this exclusive video interview, Andrew Catchpole, chief scientific officer at hVIVO, sits down with pharmaphorums Deep Dive editor Eloise McLennan to unpack exactly how these studies work and how they differ from traditional trial methods
Efficacy was maintained at week 48
doi: 10.1080/20002297.2025.2499284 142 MoosavianM.KushkiE.NavidifarT.HajianiE.MandegariM
Ifinatamab deruxtecan (DS-7300a, I-DXd), a B7-H3-targeting ADC with a potent DNA topoisomerase I inhibitor, showed promising results in 19 patients with heavily pretreated SCLC, achieving an ORR of 58%
The injectable GLP-1 RAs liraglutide 3 mg once daily and semaglutide 2.4 mg once weekly have both gained a licence for weight loss, alongside lifestyle management, in obese/overweight people without T2D (SmPC, 2023b
d , GLP-1:Lani
US$ 28.76
US$ 23.17
US$ 26.76
US$ 28.80
US$ 25.85
US$ 22.68
